High dose 5‐ASA showed no clear difference in endoscopic recurrence compared with low dose 5‐ASA (moderate certainty).
The review found no eligible studies for this question.
It is very uncertain whether 5‐ASA changes endoscopic recurrence compared with purine antimetabolites (very low certainty).
It is very uncertain whether 5‐ASAs changes endoscopic recurrence compared with anti TNF‐ɑ (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether 5‐ASAs changes endoscopic recurrence compared with placebo (very low certainty).
Intensification of prophylactic therapy guided by colonoscopy may leads to lower endoscopic recurrence ( compared with intensification guided by clinical recurrence (low certainty).
It is very uncertain whether initiation of prophylactic therapy guided by colonoscopy changes endoscopic recurrence (at week 102) compared with initiation of prophylactic therapy immediately after surgery (very low certainty).